MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 16, 2005; DOI: 10.1124/mol.104.007146


0026-895X/05/6705-1732-1739$20.00
Mol Pharmacol 67:1732-1739, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.007146v1
67/5/1732    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lankisch, T. O.
Right arrow Articles by Strassburg, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lankisch, T. O.
Right arrow Articles by Strassburg, C. P.
ORIGINAL ARTICLE

Identification and Characterization of a Functional TATA Box Polymorphism of the UDP Glucuronosyltransferase 1A7 Gene

Tim O. Lankisch, Arndt Vogel, Stefan Eilermann, Anette Fiebeler, Britta Krone, Ayse Barut, Michael P. Manns, and Christian P. Strassburg

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany (T.O.L., A.V., S.E., B.K., A.B., M.P.M., C.P.S.); and Department of Medicine of the Charite, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany (A.F.)

Abstract

UDP glucuronosyltransferases (UGT) detoxify bilirubin and therapeutic drugs, a process influenced by single nucleotide polymorphisms (SNPs) in their structural genes and promoter elements. UGT1A1*28 is a functional UGT promoter polymorphism associated with Gilbert's disease and severe irinotecan toxicity, which also occurs in the absence of UGT1A1*28. The aim of this study was to identify and characterize UGT promoter variants relevant for irinotecan detoxification. Recombinant UGT1A proteins were analyzed for irinotecan metabolite glucuronidation by UGT activity assays. In 427 healthy blood donors and 71 homozygous UGT1A1*28 carriers, the 5'-untranslated region of the UGT1A7 gene locus was studied. An SNP was detected by allelic discrimination and characterized by reporter gene experiments. A novel –57 T-> G SNP with a gene frequency of 0.39 in healthy blood donors was identified in the putative TATA box of the UGT1A7 gene, reducing promoter activity to 30%. It is in linkage dysequilibrium with a variant of the UGT1A7 first exon that is present in the reduced-activity UGT1A7*3 and UGT1A7*4 alleles. Homozygous UGT1A1*28 carriers simultaneously carried this variant in 97%. We identified a novel reduced-function TATA box SNP of the UGT1A7 gene that catalyzes irinotecan metabolite detoxification. Its association with variants of the UGT1A1 promoter and UGT1A7 gene may influence irinotecan metabolism. Our finding emphasizes the importance of combinations of structural and regulatory gene polymorphisms that may be useful as markers of drug toxicity.


Received September 14, 2004; accepted February 16, 2005

Address correspondence to: Dr. Christian P. Strassburg, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. E-mail: strassburg.christian{at}mh-hannover.de




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
T. O. Lankisch, C. Schulz, T. Zwingers, T. J. Erichsen, M. P. Manns, V. Heinemann, and C. P. Strassburg
Gilbert's Syndrome and Irinotecan Toxicity: Combination with UDP-Glucuronosyltransferase 1A7 Variants Increases Risk
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 695 - 701.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
V. J. Navarro and J. R. Senior
Drug-Related Hepatotoxicity
N. Engl. J. Med., February 16, 2006; 354(7): 731 - 739.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics